• 5F-EDMB-PICA is a potent, high-efficacy agonist at both CB1 and CB2 receptors, with sub-nanomolar affinity for CB1.
• Acute administration of 5F-EDMB-PICA dose-dependently reduces body weight, food intake, and core temperature in rats, effects that are CB1-mediated.
• The pharmacological profile of 5F-EDMB-PICA resembles that of other synthetic cannabinoids, indicating potential for adverse effects and abuse.
• This study provides critical data for risk assessment and regulatory control of this emerging synthetic cannabinoid.